
FDA approved a new drug application for Zutripro (hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine HCl) Oral Solution (CIII) and Rezira (hydrocodone bitartrate and pseudoephedrine HCl) Oral Solution (CIII), according to a statement issued by Cypress Pharmaceutical.